<DOC>
	<DOCNO>NCT00896168</DOCNO>
	<brief_summary>The purpose study compare effectiveness iInfliximab plus methotrexate ( MTX ) treatment Rheumatoid rheumatoid Arthritis arthritis ( RA ) ( autoimmune disease cause pain , swell , stiffness loss function joint ) participant moderate disease versus participant severe disease compare efficacy safety MTX subgroup .</brief_summary>
	<brief_title>An Efficacy Safety Study Infliximab Participants With Rheumatoid Arthritis</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , multi-center ( study conduct 1 center ) , prospective ( study follow participant forward time ) study compare American College Rheumatology ( ACR ) score participant moderate RA ( define score great 3.2 , less 5.1 Disease Activity Score 28 [ DAS 28 ] ) participant severe RA ( define score great 5.1 DAS 28 score ) disease treat infliximab MTX . DAS evaluate RA activity several parameter include number swell tender joint participant 's assessment pain . Participants receive infliximab 3 milligram ( mg ) per kilogram ( kg ) intravenous infusion ( drug give vein ) ( le 2 hour ) Weeks 0 , 2 , 6 , 14 22 along oral MTX stable dose 7.5 20 mg per week ( equal dose use participation study ) 22 Weeks . Participants follow-up visit Week 26 . Efficacy primarily assess percentage participant obtain ACR20 , ACR50 ACR70 response Week 26 . Participants ' safety assess throughout study .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Participants definitive diagnosis rheumatoid arthritis ( RA ) base American College Rheumatology Criteria 1987 Participants must Methotrexate ( MTX ) 12 week stable dose least 4 week Participants use oral corticosteroid , must stable dose prednisone less 10 milligram per day ( mg/day ) equivalent least 4 week screen currently use corticosteroid , participant must receive corticosteroid least 4 week screen Participants moderate severe RA ( Disease Activity Score [ DAS28 ] great 3.2 ) Male participant shall adopt contraceptive measure trial within 6 month completion trial ( spermicidal barrier ) , female sexual partner shall agree adopt effective contraceptive measure trial within 6 month completion trial ( oral contraceptive , contraceptive injection , intrauterine device [ IUD ] , sterilization surgery ) ; female participant childbearing potential negative urine pregnancy test upon enrollment addition adopt say contraceptive measure Participant know allergy human immunoglobulin proteins component infliximab Participant history receive infliximab biological preparation Participant stage IV RA evaluate Xray Participants suffer tuberculosis Female participant male participant 's wife plan become pregnant study within 6 month completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Arthritis , Rheumatoid</keyword>
	<keyword>Infliximab</keyword>
	<keyword>Methotrexate</keyword>
</DOC>